{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T07:02:24Z","timestamp":1794294144894,"version":"4.9.0"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T00:00:00Z","timestamp":1780617600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T00:00:00Z","timestamp":1786579200000},"content-version":"vor","delay-in-days":69,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Key Research and Development Plan Projects in Shaanxi Province","award":["2021SF-133"],"award-info":[{"award-number":["2021SF-133"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Gastroenterol"],"DOI":"10.1186\/s12876-026-04983-3","type":"journal-article","created":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T00:46:22Z","timestamp":1780620382000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Association of a novel Fat-Muscle-BMI Index (FMBI) with NAFLD, liver fibrosis, and atherosclerotic cardiovascular disease risk: a cross-sectional study in 1,592 Chinese adults"],"prefix":"10.1186","volume":"26","author":[{"given":"Xiaokang","family":"Wu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinjiang","family":"Hou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiafeng","family":"Yin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chaoliang","family":"Xiong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hailong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Meng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,5]]},"reference":[{"issue":"suppl","key":"4983_CR1","doi-asserted-by":"publisher","first-page":"S5","DOI":"10.3350\/cmh.2022.0424","volume":"29","author":"SK Han","year":"2023","unstructured":"Han SK, Baik SK, Kim MY. Non-alcoholic fatty liver disease: definition and subtypes. Clin Mol Hepatol. 2023;29(suppl):S5-s16.","journal-title":"Clin Mol Hepatol"},{"issue":"10290","key":"4983_CR2","doi-asserted-by":"publisher","first-page":"2212","DOI":"10.1016\/S0140-6736(20)32511-3","volume":"397","author":"EE Powell","year":"2021","unstructured":"Powell EE, Wong VW, Rinella M. Non-alcoholic fatty liver disease. Lancet (London, England). 2021;397(10290):2212\u201324.","journal-title":"Lancet (London, England)"},{"issue":"4","key":"4983_CR3","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1016\/j.jhep.2021.10.025","volume":"76","author":"JV Lazarus","year":"2022","unstructured":"Lazarus JV, Mark HE, Villota-Rivas M, Palayew A, Carrieri P, Colombo M, et al. The global NAFLD policy review and preparedness index: are countries ready to address this silent public health challenge? J Hepatol. 2022;76(4):771\u201380.","journal-title":"J Hepatol"},{"issue":"1","key":"4983_CR4","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1038\/s41575-021-00523-4","volume":"19","author":"JV Lazarus","year":"2022","unstructured":"Lazarus JV, Mark HE, Anstee QM, Arab JP, Batterham RL, Castera L, et al. Advancing the global public health agenda for NAFLD: a consensus statement. Nat Rev Gastroenterol Hepatol. 2022;19(1):60\u201378.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"6","key":"4983_CR5","doi-asserted-by":"publisher","first-page":"1966","DOI":"10.1097\/HEP.0000000000000520","volume":"78","author":"ME Rinella","year":"2023","unstructured":"Rinella ME, Lazarus JV, Ratziu V, Francque SM, Sanyal AJ, Kanwal F, et al. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. Hepatology (Baltimore, MD). 2023;78(6):1966\u201386.","journal-title":"Hepatology (Baltimore, MD)"},{"issue":"1","key":"4983_CR6","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/S2468-1253(22)00317-X","volume":"8","author":"J Quek","year":"2023","unstructured":"Quek J, Chan KE, Wong ZY, Tan C, Tan B, Lim WH, et al. Global prevalence of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in the overweight and obese population: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2023;8(1):20\u201330.","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"3","key":"4983_CR7","doi-asserted-by":"publisher","first-page":"391","DOI":"10.4093\/dmj.2022.0048","volume":"46","author":"XL Zhang","year":"2022","unstructured":"Zhang XL, Wang TY, Targher G, Byrne CD, Zheng MH. Lifestyle interventions for non-obese patients both with, and at risk, of non-alcoholic fatty liver disease. Diabetes Metab J. 2022;46(3):391\u2013401.","journal-title":"Diabetes Metab J"},{"key":"4983_CR8","doi-asserted-by":"publisher","first-page":"113331","DOI":"10.1016\/j.biopha.2022.113331","volume":"153","author":"R Xu","year":"2022","unstructured":"Xu R, Pan J, Zhou W, Ji G, Dang Y. Recent advances in lean NAFLD. Biomed Pharmacother. 2022;153:113331.","journal-title":"Biomed Pharmacother"},{"issue":"2","key":"4983_CR9","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1007\/s12072-022-10304-z","volume":"16","author":"D Chahal","year":"2022","unstructured":"Chahal D, Sharma D, Keshavarzi S, Arisar FAQ, Patel K, Xu W, et al. Distinctive clinical and genetic features of lean vs overweight fatty liver disease using the UK Biobank. Hepatol Int. 2022;16(2):325\u201336.","journal-title":"Hepatol Int"},{"issue":"1","key":"4983_CR10","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1186\/s12967-023-04047-0","volume":"21","author":"S Lu","year":"2023","unstructured":"Lu S, Xie Q, Kuang M, Hu C, Li X, Yang H, Sheng G, Xie G, Zou Y. Lipid metabolism, BMI and the risk of nonalcoholic fatty liver disease in the general population: evidence from a mediation analysis. J Transl Med. 2023;21(1):192.","journal-title":"J Transl Med"},{"key":"4983_CR11","doi-asserted-by":"publisher","first-page":"154911","DOI":"10.1016\/j.metabol.2021.154911","volume":"126","author":"EX Tan","year":"2022","unstructured":"Tan EX, Lee JW, Jumat NH, Chan WK, Treeprasertsuk S, Goh GB, et al. Non-obese non-alcoholic fatty liver disease (NAFLD) in Asia: an international registry study. Metabolism. 2022;126:154911.","journal-title":"Metabolism"},{"key":"4983_CR12","doi-asserted-by":"crossref","unstructured":"Wang X, Rao H, Liu F, Wei L, Li H, Wu C. Recent advances in adipose tissue dysfunction and its role in the pathogenesis of non-alcoholic fatty liver disease. Cells. 2021;10(12):3300.","DOI":"10.3390\/cells10123300"},{"issue":"1","key":"4983_CR13","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1016\/j.cgh.2021.10.033","volume":"21","author":"J Li","year":"2023","unstructured":"Li J, Allen AM, Shah VH, Manduca A, Ehman RL, Yin M. Longitudinal changes in MR elastography-based biomarkers in obese patients treated with bariatric surgery. Clin Gastroenterol Hepatol. 2023;21(1):220-222.e223.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"7","key":"4983_CR14","doi-asserted-by":"publisher","first-page":"1576","DOI":"10.1111\/liv.14899","volume":"41","author":"S Lang","year":"2021","unstructured":"Lang S, Martin A, Zhang X, Farowski F, Wisplinghoff H, M JGTV, et al. Combined analysis of gut microbiota, diet and PNPLA3 polymorphism in biopsy-proven non-alcoholic fatty liver disease. Liver Int. 2021;41(7):1576\u201391.","journal-title":"Liver Int"},{"issue":"2","key":"4983_CR15","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1111\/liv.15436","volume":"43","author":"B Feng","year":"2023","unstructured":"Feng B, Chen S, Wang X, Hu S, Zhang X, Zhang J, et al. Effect of cumulative body mass index exposure and long-term related change on incident non-alcoholic fatty liver disease. Liver Int. 2023;43(2):345\u201356.","journal-title":"Liver Int"},{"key":"4983_CR16","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1016\/j.diabres.2018.02.009","volume":"139","author":"N Kurinami","year":"2018","unstructured":"Kurinami N, Sugiyama S, Morita A, Yoshida A, Hieshima K, Miyamoto F, et al. Ratio of muscle mass to fat mass assessed by bioelectrical impedance analysis is significantly correlated with liver fat accumulation in patients with type 2 diabetes mellitus. Diabetes Res Clin Pract. 2018;139:122\u201330.","journal-title":"Diabetes Res Clin Pract"},{"issue":"6","key":"4983_CR17","doi-asserted-by":"publisher","first-page":"412","DOI":"10.3961\/jpmph.21.387","volume":"54","author":"HJ Lee","year":"2021","unstructured":"Lee HJ, Chang JS, Ahn JH, Kim MY, Park KS, Ahn YS, et al. Association between low muscle mass and non-alcoholic fatty liver disease diagnosed using ultrasonography, magnetic resonance imaging derived proton density fat fraction, and comprehensive NAFLD score in Korea. J Prev Med Public Health. 2021;54(6):412\u201321.","journal-title":"J Prev Med Public Health"},{"issue":"4","key":"4983_CR18","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1007\/s00535-017-1377-3","volume":"53","author":"T Shida","year":"2018","unstructured":"Shida T, Akiyama K, Oh S, Sawai A, Isobe T, Okamoto Y, et al. Skeletal muscle mass to visceral fat area ratio is an important determinant affecting hepatic conditions of non-alcoholic fatty liver disease. J Gastroenterol. 2018;53(4):535\u201347.","journal-title":"J Gastroenterol"},{"key":"4983_CR19","doi-asserted-by":"publisher","first-page":"2067","DOI":"10.2147\/DMSO.S526335","volume":"18","author":"L Zhang","year":"2025","unstructured":"Zhang L, Sun Y, Zhao Y, Wu X, Han X. Relationship between fat-to-muscle ratio and nonalcoholic fatty liver disease in middle-aged and older adults with type 2 diabetes: cross-sectional study. Diabetes Metab Syndr Obes. 2025;18:2067\u201376.","journal-title":"Diabetes Metab Syndr Obes"},{"key":"4983_CR20","doi-asserted-by":"publisher","first-page":"495","DOI":"10.2147\/DMSO.S185705","volume":"12","author":"T Shida","year":"2019","unstructured":"Shida T, Oshida N, Oh S, Okada K, Shoda J. Progressive reduction in skeletal muscle mass to visceral fat area ratio is associated with a worsening of the hepatic conditions of non-alcoholic fatty liver disease. Diabetes Metab Syndr Obes. 2019;12:495\u2013503.","journal-title":"Diabetes Metab Syndr Obes"},{"issue":"9","key":"4983_CR21","doi-asserted-by":"publisher","first-page":"2238","DOI":"10.1002\/hep4.1975","volume":"6","author":"Y Cho","year":"2022","unstructured":"Cho Y, Chang Y, Ryu S, Jung HS, Kim CW, Oh H, et al. Skeletal muscle mass to visceral fat area ratio as a predictor of NAFLD in lean and overweight men and women with effect modification by sex. Hepatol Commun. 2022;6(9):2238\u201352.","journal-title":"Hepatol Commun"},{"issue":"3","key":"4983_CR22","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1111\/liv.14719","volume":"41","author":"YC Hsieh","year":"2021","unstructured":"Hsieh YC, Joo SK, Koo BK, Lin HC, Kim W. Muscle alterations are independently associated with significant fibrosis in nonalcoholic fatty liver disease. Liver Int. 2021;41(3):494\u2013504.","journal-title":"Liver Int"},{"key":"4983_CR23","doi-asserted-by":"publisher","unstructured":"XiY, Liang Z, Jin H, Jiang Y, Tan R, Zhang Y, Wang J, Sui W, Liu B, Zhang H et al. Association of total and regional fat-to-muscle ratio with the risk of metabolic dysfunction-associated fatty liver disease and other chronic liver diseases. Hepatol Intern. 2026. Online ahead of print. https:\/\/doi.org\/10.1007\/s12072-026-11064-w.","DOI":"10.1007\/s12072-026-11064-w"},{"issue":"1","key":"4983_CR24","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1186\/s12986-021-00551-6","volume":"18","author":"H Dai","year":"2021","unstructured":"Dai H, Xiang J, Hou Y, Xuan L, Wang T, Li M, et al. Fat mass to fat-free mass ratio and the risk of non-alcoholic fatty liver disease and fibrosis in non-obese and obese individuals. Nutr Metab. 2021;18(1):21.","journal-title":"Nutr Metab"},{"issue":"17","key":"4983_CR25","doi-asserted-by":"publisher","first-page":"e030101","DOI":"10.1161\/JAHA.123.030101","volume":"12","author":"R Zhou","year":"2023","unstructured":"Zhou R, Chen HW, Lin Y, Li FR, Zhong Q, Huang YN, et al. Total and regional fat\/muscle mass ratio and risks of incident cardiovascular disease and mortality. J Am Heart Assoc. 2023;12(17):e030101.","journal-title":"J Am Heart Assoc"},{"key":"4983_CR26","doi-asserted-by":"crossref","unstructured":"Li J, Xi F, He Y, Sun C, Yu W, Wang X. High fat-to-muscle ratio was associated with increased clinical severity in patients with abdominal trauma. J Clin Med. 2023;12(4):1503.","DOI":"10.3390\/jcm12041503"},{"key":"4983_CR27","doi-asserted-by":"publisher","first-page":"112155","DOI":"10.1016\/j.exger.2023.112155","volume":"175","author":"H He","year":"2023","unstructured":"He H, Pan L, Wang D, Liu F, Du J, Pa L, et al. The association between muscle-to-fat ratio and cardiometabolic risks: the China National Health Survey. Exp Gerontol. 2023;175:112155.","journal-title":"Exp Gerontol"},{"issue":"10","key":"4983_CR28","doi-asserted-by":"publisher","first-page":"e072489","DOI":"10.1136\/bmjopen-2023-072489","volume":"13","author":"F Yan","year":"2023","unstructured":"Yan F, Nie G, Zhou N, Zhang M, Peng W. Association of fat-to-muscle ratio with nonalcoholic fatty liver disease: a single-centre retrospective study. BMJ Open. 2023;13(10):e072489.","journal-title":"BMJ Open"},{"issue":"9","key":"4983_CR29","doi-asserted-by":"publisher","first-page":"2298","DOI":"10.1016\/j.cgh.2022.11.031","volume":"21","author":"HS Chun","year":"2023","unstructured":"Chun HS, Lee M, Lee HA, Lee S, Kim S, Jung YJ, et al. Risk stratification for sarcopenic obesity in subjects with Nonalcoholic Fatty Liver Disease. Clin Gastroenterol Hepatol. 2023;21(9):2298-2307.e2218.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"2","key":"4983_CR30","doi-asserted-by":"publisher","first-page":"129","DOI":"10.7570\/jomes.2019.28.2.129","volume":"28","author":"GE Chung","year":"2019","unstructured":"Chung GE, Kim MJ, Yim JY, Kim JS, Yoon JW. Sarcopenia is significantly associated with presence and severity of Nonalcoholic Fatty Liver Disease. J Obes Metab Syndr. 2019;28(2):129\u201338.","journal-title":"J Obes Metab Syndr"},{"issue":"6","key":"4983_CR31","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1007\/s12072-019-09996-7","volume":"13","author":"JA Kim","year":"2019","unstructured":"Kim JA, Choi KM. Sarcopenia and fatty liver disease. Hepatol Int. 2019;13(6):674\u201387.","journal-title":"Hepatol Int"},{"key":"4983_CR32","doi-asserted-by":"publisher","first-page":"155676","DOI":"10.1016\/j.metabol.2023.155676","volume":"147","author":"SA Polyzos","year":"2023","unstructured":"Polyzos SA, Vachliotis ID, Mantzoros CS. Sarcopenia, sarcopenic obesity and nonalcoholic fatty liver disease. Metabolism. 2023;147:155676.","journal-title":"Metabolism"},{"issue":"2","key":"4983_CR33","doi-asserted-by":"publisher","first-page":"227","DOI":"10.15403\/jgld-3323","volume":"30","author":"K Wijarnpreecha","year":"2021","unstructured":"Wijarnpreecha K, Aby ES, Ahmed A, Kim D. Association between sarcopenic obesity and nonalcoholic fatty liver disease and fibrosis detected by fibroscan. J Gastrointestin Liver Dis. 2021;30(2):227\u201332.","journal-title":"J Gastrointestin Liver Dis"},{"key":"4983_CR34","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.clnesp.2020.05.025","volume":"38","author":"K Kashiwagi","year":"2020","unstructured":"Kashiwagi K, Takayama M, Fukuhara K, Shimizu-Hirota R, Chu PS, Nakamoto N, et al. A significant association of non-obese Nonalcoholic Fatty Liver Disease with sarcopenic obesity. Clin Nutr ESPEN. 2020;38:86\u201393.","journal-title":"Clin Nutr ESPEN"},{"issue":"10","key":"4983_CR35","doi-asserted-by":"publisher","first-page":"1392","DOI":"10.1016\/j.dld.2019.02.019","volume":"51","author":"C Shao","year":"2019","unstructured":"Shao C, Ye J, Li F, Feng S, Wang W, Zhong B. Different predictors of steatosis and fibrosis severity among lean, overweight and obese patients with nonalcoholic fatty liver disease. Dig Liver Dis. 2019;51(10):1392\u20139.","journal-title":"Dig Liver Dis"},{"key":"4983_CR36","doi-asserted-by":"crossref","unstructured":"Jin H, Oh HJ, Lee BY. GABA prevents age-related sarcopenic obesity in mice with high-fat-diet-induced obesity. Cells. 2023;12(17):2146.","DOI":"10.3390\/cells12172146"},{"issue":"11","key":"4983_CR37","first-page":"809","volume":"129","author":"K Maliszewska","year":"2019","unstructured":"Maliszewska K, Adamska-Patruno E, Kr\u0119towski A. The interplay between muscle mass decline, obesity, and type 2 diabetes. Pol Arch Intern Med. 2019;129(11):809\u201316.","journal-title":"Pol Arch Intern Med"},{"key":"4983_CR38","doi-asserted-by":"publisher","first-page":"1693123","DOI":"10.3389\/fendo.2025.1693123","volume":"16","author":"P Dey","year":"2025","unstructured":"Dey P. The emerging phenotype of Nonalcoholic Fatty Liver Disease in lean individuals: what\u2019s different? Front Endocrinol. 2025;16:1693123.","journal-title":"Front Endocrinol"},{"issue":"3","key":"4983_CR39","first-page":"185","volume":"22","author":"M Merli","year":"2019","unstructured":"Merli M, Lattanzi B, Aprile F. Sarcopenic obesity in fatty liver. Curr Opin Clin Nutr Metab Care. 2019;22(3):185\u201390.","journal-title":"Curr Opin Clin Nutr Metab Care"},{"issue":"5","key":"4983_CR40","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1002\/osp4.509","volume":"7","author":"DJ Hanna","year":"2021","unstructured":"Hanna DJ, Jamieson ST, Lee CS, Pluskota CA, Bressler NJ, Benotti PN, et al. Bioelectrical impedance analysis in managing sarcopenic obesity in NAFLD. Obes Sci Pract. 2021;7(5):629\u201345.","journal-title":"Obes Sci Pract"},{"key":"4983_CR41","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.maturitas.2019.03.016","volume":"124","author":"K Wijarnpreecha","year":"2019","unstructured":"Wijarnpreecha K, Panjawatanan P, Aby E, Ahmed A, Kim D. Nonalcoholic fatty liver disease in the over-60s: impact of sarcopenia and obesity. Maturitas. 2019;124:48\u201354.","journal-title":"Maturitas"},{"key":"4983_CR42","doi-asserted-by":"crossref","unstructured":"Iwaki M, Kobayashi T, Nogami A, Saito S, Nakajima A, Yoneda M. Impact of sarcopenia on non-alcoholic fatty liver disease. Nutrients. 2023;15(4):891.","DOI":"10.3390\/nu15040891"},{"issue":"Suppl","key":"4983_CR43","doi-asserted-by":"publisher","first-page":"S68","DOI":"10.3350\/cmh.2022.0358","volume":"29","author":"SK Joo","year":"2023","unstructured":"Joo SK, Kim W. Interaction between sarcopenia and nonalcoholic fatty liver disease. Clin Mol Hepatol. 2023;29(Suppl):S68-s78.","journal-title":"Clin Mol Hepatol"},{"key":"4983_CR44","doi-asserted-by":"publisher","first-page":"774030","DOI":"10.3389\/fnut.2021.774030","volume":"8","author":"V Zambon Azevedo","year":"2021","unstructured":"Zambon Azevedo V, Silaghi CA, Maurel T, Silaghi H, Ratziu V, Pais R. Impact of sarcopenia on the severity of the liver damage in patients with non-alcoholic fatty liver disease. Front Nutr. 2021;8:774030.","journal-title":"Front Nutr"},{"key":"4983_CR45","first-page":"8859719","volume":"2020","author":"I Mikolasevic","year":"2020","unstructured":"Mikolasevic I, Pavic T, Kanizaj TF, Bender DV, Domislovic V, Krznaric Z. Nonalcoholic fatty liver disease and sarcopenia: where do we stand? Can J Gastroenterol Hepatol. 2020;2020:8859719.","journal-title":"Can J Gastroenterol Hepatol"},{"key":"4983_CR46","doi-asserted-by":"crossref","unstructured":"Ferenc K, Jarmakiewicz-Czaja S, Filip R. What does sarcopenia have to do with nonalcoholic fatty liver disease? Life (Basel, Switzerland). 2023;14(1):37.","DOI":"10.3390\/life14010037"},{"issue":"2","key":"4983_CR47","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1080\/14656566.2021.1978978","volume":"23","author":"CS Hsu","year":"2022","unstructured":"Hsu CS, Kao JH. Management of non-alcoholic fatty liver disease in patients with sarcopenia. Expert Opin Pharmacother. 2022;23(2):221\u201333.","journal-title":"Expert Opin Pharmacother"},{"issue":"8","key":"4983_CR48","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1080\/00365521.2017.1315169","volume":"52","author":"ID Munsterman","year":"2017","unstructured":"Munsterman ID, Smits MM, Andriessen R, van Nieuwkerk CMJ, Bloemena E, Mulder CJJ, et al. Smoking is associated with severity of liver fibrosis but not with histological severity in nonalcoholic fatty liver disease. results from a cross-sectional study. Scand J Gastroenterol. 2017;52(8):881\u20135.","journal-title":"Scand J Gastroenterol"},{"key":"4983_CR49","doi-asserted-by":"publisher","first-page":"1015919","DOI":"10.3389\/fpubh.2023.1015919","volume":"11","author":"YS Jang","year":"2023","unstructured":"Jang YS, Joo HJ, Park YS, Park EC, Jang SI. Association between smoking cessation and non-alcoholic fatty liver disease using NAFLD liver fat score. Front Public Health. 2023;11:1015919.","journal-title":"Front Public Health"},{"issue":"6","key":"4983_CR50","doi-asserted-by":"publisher","first-page":"e0325305","DOI":"10.1371\/journal.pone.0325305","volume":"20","author":"H Joe","year":"2025","unstructured":"Joe H, Oh JE, Cho YJ, Shin HS. Association between smoking status and non-alcoholic fatty liver disease. PLoS ONE. 2025;20(6):e0325305.","journal-title":"PLoS ONE"},{"key":"4983_CR51","doi-asserted-by":"crossref","unstructured":"Xu J, Li Y, Feng Z, Chen H. Cigarette smoke contributes to the progression of MASLD: from the molecular mechanisms to therapy. Cells. 2025;14(3):221.","DOI":"10.3390\/cells14030221"},{"key":"4983_CR52","doi-asserted-by":"publisher","first-page":"1788704","DOI":"10.3389\/fnut.2026.1788704","volume":"13","author":"L Song","year":"2026","unstructured":"Song L, Zhang L, Hang Y, Yang Z, Yang J, Wang D. The development and evaluation of nine non-conventional lipid parameters for metabolic dysfunction-associated fatty liver disease in Chinese medical health examination adults: a single-center retrospective study. Front Nutr. 2026;13:1788704.","journal-title":"Front Nutr"}],"container-title":["BMC Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12876-026-04983-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-026-04983-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-026-04983-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T22:33:52Z","timestamp":1786574032000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12876-026-04983-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,5]]},"references-count":52,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4983"],"URL":"https:\/\/doi.org\/10.1186\/s12876-026-04983-3","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-9304928\/v1","asserted-by":"object"}]},"ISSN":["1471-230X"],"issn-type":[{"value":"1471-230X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,5]]},"assertion":[{"value":"2 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study involved the Publicly open-data from the Dryad digital repository including raw available clinical information data collected by other research teams from various countries and hospitals, has been used and analyzed by some studies. This data was from individuals who underwent routine health check-ups at Wuhan Union Hospital from January 2020 to November 2021, and the study protocol was approved by the Ethics Committee of Wuhan Tongji Medical College (S155), and all procedures were performed in accordance with the relevant guidelines and regulations, including the Declaration of Helsinki.Not applicable. This study is a secondary analysis of publicly available, anonymized data from the Dryad digital repository. The original study was approved by the Ethics Committee of Wuhan Tongji Medical College (S155), which waived the requirement for individual informed consent.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable. This manuscript does not contain any individual person\u2019s data in any form (including images, videos, or clinical details) that would compromise anonymity.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"501"}}